Key result
All-trans retinoic acid treatment in glomerulosclerosis rats down-regulated ACE1, angiotensin I, and angiotensin II expression, and increased ACE2 expression compared to untreated rats.
Why the study?
Does all-trans retinoic acid (ATRA) treatment alter renin-angiotensin aldosterone system (RAAS) expression in a rat model of glomerulosclerosis?
Does all-trans retinoic acid (ATRA) treatment alter renin-angiotensin aldosterone system (RAAS) expression in a rat model of glomerulosclerosis?
In a rat model of glomerulosclerosis, ATRA treatment favorably modulates RAAS expression by down-regulating ACE1 and up-regulating ACE2.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating in rat glomerulosclerosis; leaves open translation to human RAAS modulation or glomerular disease therapy.
BACKGROUND AND OBJECTIVE: All-trans retinoic acid (ATRA), a promising therapeutic agent, has been confirmed in animal experiments as playing a protective role against renal diseases. The renin-angiotensin aldosterone system (RAAS) plays a key role in the pathogenesis of renal diseases, and RAAS inhibitors can prevent the progression of kidney diseases. In our previous study, we found that ATRA could play a protective role against glomerulosclerosis (GS) lesions in rats, and its effect was similar to RAAS inhibitors. However, whether ATRA treatment was associated with RAAS expression was not clear. METHODS: Six-week-old male Wistar rats were divided into three groups: sham operation group (SHO), glomerulosclerosis model group without treatment (GS) and GS model group treated with ATRA (GA). At the end of 13 weeks, the relevant samples were collected and analyzed. RESULTS: The mRNA and protein expression of angiotensin-converting enzyme 1 (ACE1) in the GS group was notably higher when compared with the SHO group. However, mRNA and protein expression of ACE1 in the ATRA treatment group was markedly down-regulated when compared with the GS group. Angiotensin-converting enzyme 2 (ACE2) expression (mRNA or protein) in the GS group was reduced compared with that in the SHO group, and ATRA markedly increased the mRNA and protein expression of ACE2 compared with the GS group. The levels of protein expression of angiotensin I and angiotensin II were significantly up-regulated in the GS group compared with those in the SHO group, and ATRA reduced their expression in the GA group when compared with the GS group. CONCLUSION: ATRA is associated with RAAS expression in GS rats, but its detailed mechanism needs to be elucidated by further research.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2012) studied Glomerulosclerosis. All-trans retinoic acid (ATRA) vs. Glomerulosclerosis model without treatment (GS) and sham operation (SHO) was evaluated on mRNA and protein expression of ACE1, ACE2, angiotensin I, and angiotensin II. All-trans retinoic acid treatment in glomerulosclerosis rats down-regulated ACE1, angiotensin I, and angiotensin II expression, and increased ACE2 expression compared to untreated rats.
Synapse has enriched 10 related papers. Consider them for comparative context: